High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

Learn how targeted therapy and advanced blood analysis transformed treatment for erthyroderma, a rare inflammatory skin ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management. Now a new study could pave the ...

Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support ...

When the patient was treated with a dual therapy of two monoclonal antibodies, dupilumab and secukinumab, his symptoms dramatically decreased and eventually resolved, essentially curing him of his ...

Botulinum toxin type A may help reduce inflammation in hidradenitis suppurativa (HS) by inhibiting mast cell degranulation.

Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.

active ingredient secukinumab) biosimilar. Cosentyx is an interleukin (IL)-17A inhibitor developed by the Swiss pharmaceutical company Novartis, used to treat autoimmune diseases such as ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...